Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Award

Dr. Kathryn Moore

Kathryn Moore, Ph.D.

New York University
New York, NY

Title: Innate immune signaling in Alzheimer's disease pathogenesis
Non-Technical Title: Role of the innate immune response in the development of Alzheimer's disease

Duration: April 1, 2008 - March 31, 2011
Award Type: Standard
Award Amount: $265,000


Summary:

This award seeks to study the role of the innate immune system in AD pathogenesis. and the role of Toll-like recceptors in mediating the microglial inflammatory response. Microglia likely play a key role in the clearance of Aß as well as in more chronic inflammatory changes as a result of Aß activation.

Details:

Microglia are the primary immune cells of the brain and in Alzheimer's disease (AD) these cells accumulate at sites of ß-amyloid (Aß) deposits, including senile plaques. Microglial interactions with Aß incite a chronic inflammatory response that leads to neuronal degeneration, increased Aß deposition and disease progression. The microglial receptors and signaling pathways triggered by Aß that promote this chronic inflammation remain a matter of speculation. Our long-term goals are to identify the mechanisms of microglial activation by Aß and the impact of these pathways on disease. We hypothesize that the Toll-like receptors (TLR), an evolutionarily ancient family of microbial recognition receptors, initiate and maintain the microglial inflammatory response to Aß. This hypothesis is based on preliminary findings that targeting of members of this signaling pathway block microglial inflammatory responses to Aß. We propose to define the TLRs and co-receptors responsible for initiating this signalling, their impact on microglial inflammatory responses and the implications for disease. Understanding the mechanism(s) of microglial interactions with Aß and identifying the receptors involved in these interactions will provide valuable insight into the role of these cells in the pathogenesis of AD and potentially identify therapeutic targets in AD.